Insmed in-licenses DPP-1 inhibitor from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted pulmonary disease company Insmed Inc. (NASDAQ:INSM) exclusive, worldwide rights to AZD7986, a small molecule inhibitor of dipeptidyl peptidase-1 ( DPP-1; CTSC).

The candidate, which Insmed renamed INS1007, has completed Phase I testing. Next year, Insmed plans to start a Phase II study of the compound to treat non-cystic fibrosis (CF) bronchiectasis, a rare pulmonary disorder in which the bronchi become permanently dilated. ...